XSpray Pharma
Xspray Pharma AB is a clinical-stage Swedish biopharmaceutical enterprise headquartered in Solna, Sweden. The company focuses on developing improved and bioequivalent versions of established kinase inhibitors used in targeted cancer therapies. Its proprietary Hyhalo technology platform enhances the solubility and bioavailability of difficult-to-formulate oncology drugs to improve patient treatment efficacy. Principal revenue is currently derived through research grants, pharmaceutical partnerships, and licensing agreements as products advance toward commercial approval. The enterprise serves oncology medical researchers and healthcare networks. Xspray Pharma AB is publicly listed on Nasdaq Stockholm.
3 of the funds FundTelligence covers report a position in XSpray Pharma.
- Legal name
- XSpray Pharma AB
- Sector
- Health Care
- Country
- Sweden
- Funds holding it
- 3
Funds holding XSpray Pharma
- Storebrand Sverige Småbolag Plus — Storebrand · 0.02 % (full portfolio disclosed, October 2026)
- Handelsbanken Norden Index Criteria — Handelsbanken · 0.01 % (full portfolio disclosed, October 2026)
- Storebrand Sverige Plus — Storebrand · 0.01 % (full portfolio disclosed, October 2026)